Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

BACKGROUND: There is no established second-line treatment after failure of gemcitabine plus nab-paclitaxel (GnP) therapy for metastatic pancreatic cancer (MPC). The purpose of this study was to evaluate the efficacy and tolerability of the modified FOLFIRINOX (mFFX) as a second-line therapy for MPC...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawada, Masashi, Kasuga, Akiyoshi, Mie, Takafumi, Furukawa, Takaaki, Taniguchi, Takanobu, Fukuda, Koshiro, Yamada, Yuto, Takeda, Tsuyoshi, Kanata, Ryo, Matsuyama, Masato, Sasaki, Takashi, Ozaka, Masato, Sasahira, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238500/
https://www.ncbi.nlm.nih.gov/pubmed/32434547
http://dx.doi.org/10.1186/s12885-020-06945-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238500/
https://www.ncbi.nlm.nih.gov/pubmed/32434547
http://dx.doi.org/10.1186/s12885-020-06945-8

Ejemplares similares